Skip to main content

Table 7 Known groups analyses: Median values, test statistics and p values for the known group’s analysis based on the T3 RTOG physician ratings, cancer type, upper and lower age quartiles and the presence of comorbidities

From: International validation of the EORTC QLQ-PRT20 module for assessment of quality of life symptoms relating to radiation proctitis: a phase IV study

QLQ PRT20 Proposed Scale T3 RTOGa: 0 (n = 108) vs. 1 (n = 153) vs. 2–3c (n = 36) Cancer Sitea: Prostate (n = 264, male) vs. Cervix (n = 18, female) vs. Rectum (n = 28, M/F = 20/8) Age quartilesb: lower ≤63 years (n = 88) vs. upper > 74 years (n = 95) Presence of comorbiditiesb: No (n = 162) vs. Yes (n = 196).
Bowel Control 8.3 vs 16.7 vs 25: H(2) = 19.9, p < .001
Bloating and Gas 8.3 vs 16.7 vs 33.3: H(2) = 20.5, p < .001 16.7 vs 33.3 vs 16.7: H(2) = 38.3, p < .001 25.0 vs 13.9, U = 2252.5, p = 0.007
Emotional Function/Lifestyle 0.0 vs 20.0 vs 33.3: H(2) = 51.4, p < .001 6.7 vs 40.0 vs 36.7: H(2) = 12.8, p = .002 13.3 vs 6.7, U = 2177.5, p = 0.003 13.3 vs 10.0, U = 11,742.5, p = .034
Pain 0.0 vs 11.1 vs 16.7: H(2) = 20.5, p < .001 16.7 vs 33.3 vs 16.7: H(2) = 7.1, p = .028
Leakage 0.0 vs 0.0 vs 16.7: H(2) = 18.1, p < .001
  1. aIndependent samples Kruskal Wallis Test – H(degrees of freedom), b Independent samples Mann-Whitney U test, c T3 RTOG ratings above 2 were collapsed into the 2–3 group (there were no category 4 ratings)
  2. NB Nonsignificant results not shown